Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

Is retatrutide FDA approved?

No, as of 2026, retatrutide has not yet been approved by the FDA or EMA. It is currently undergoing Phase 3 clinical trials focusing on safety and efficacy markers including weight-loss, liver fat reduction, and dysesthesia tracking.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Price and Cost FAQ: What to Expect and Alternatives

Retatrutide, Eli Lilly's investigational triple agonist, delivers up to 29% weight loss in Phase 3 trials for obesity and type 2 diabetes.[1] Current retatrutide price options include $150–$500 monthly for grey-market research peptides, $200–$600 for compounded telehealth versions, free clinical trial access, and projected $1,000–$1,500 per month post-FDA approval in 2027–2028. Weighing these retatrutide price points against legal risks, efficacy data, safety, and alternatives is key for informed decisions.

What Is Retatrutide and Why Does Its Price Matter?

Retatrutide (LY3437943) is a once-weekly injectable peptide that activates GLP-1, GIP, and glucagon receptors to suppress appetite, improve insulin sensitivity, and boost energy expenditure.[2] For deeper insights into its retatrutide triple agonist mechanism, explore the dedicated article. This advanced mechanism promises superior results over dual agonists like tirzepatide, fueling demand and scrutiny of the retatrutide price.

Retatrutide Overview: Triple Agonist Mechanism from Eli Lilly

Eli Lilly developed retatrutide as a 39-amino-acid synthetic peptide with a molecular weight of 4731.33 g/mol (CAS 2381089-83-2).[2] It features structural modifications like Aib residues and a C20 fatty diacid for extended half-life and albumin binding. Phase 2 trials, published in the New England Journal of Medicine, demonstrated 17–24% weight loss over 48 weeks, highlighting why retatrutide price discussions are heating up.[1]

Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP), retatrutide's glucagon activation enhances fat burning without muscle loss.[2] Purity in research forms exceeds 99% via HPLC and mass spectrometry.[2] This potency positions it as a potential game-changer, but availability drives variable retatrutide price in pre-approval markets.

Current Development Stage: Phase 3 Trials and FDA Timeline

Retatrutide advances through Phase 3, with trials wrapping by early 2026.[2] Key programs include TRIUMPH for cardiovascular and kidney outcomes in obesity (NCT06383390)[2] and TRANSCEND-T2D for diabetes (NCT06354660, topline results March 2026).[3] Full datasets are slated for ADA 2026.

FDA submission could occur late 2026, with approval in 2027–2028 pending 6–10 month review.[2] Until then, retatrutide price reflects unregulated sources rather than commercial stability. Over 2,000 participants enrolled underscore robust progress.[2]

Key Indications: Obesity, Type 2 Diabetes, and Beyond

Primary targets are obesity (BMI ≥27 with comorbidities) and type 2 diabetes.[2] Ongoing studies probe obstructive sleep apnea, knee osteoarthritis, metabolic dysfunction-associated steatotic liver disease (MASLD), and chronic low back pain.[2] Up to 29% weight loss (71 lbs average) in osteoarthritis trials signals broad utility.[1]

These indications amplify retatrutide price interest among patients frustrated with current options. Check ClinicalTrials.gov for eligibility in related studies.[4]

Current Retatrutide Price for Research Peptides (Grey Market)

Research peptides from suppliers like Polaris Peptides are labeled "not for human consumption" yet sought for off-label use. Prices hinge on vial size, purity (>99%), and quantity.[2] At clinical doses (4–12mg/week or 16–48mg/month), expect $150–$500 monthly.

These lyophilized powders require bacteriostatic water reconstitution and 2–8°C storage. Quality varies; always demand COAs. Risks include impurities and legal issues.

Research Peptide Pricing Breakdown: $40–$120 per 5mg Vial

Smaller 5mg vials range $40–$120, dropping per-mg cost for bulk (10–20mg). For example, 32–48mg monthly needs 2–4 vials, pushing totals to $150 minimum.

Factors like shipping ($20–50) and discounts affect final retatrutide price. Vendors like NovoPro Labs offer competitive rates with TFA-free options.

Polaris Peptides Retatrutide Price: 24mg ($165–$220), 35mg ($320)

Polaris Peptides stands out with 24mg vials at $165–$220 and 35mg at $320, ideal for 4–6 week supplies at high doses. Some listings require login; purity verified at 99.4%+.

User forums praise Polaris for consistency. Visit polarispeptides.com (research only, rel=nofollow) for current stock. This makes Polaris a benchmark for retatrutide price comparisons.

Other Suppliers and Monthly Costs at Clinical Doses ($150–$500)

Alternatives like NovoPro (20mg ~$165) or Medica Depot span $30–$360 per vial. Monthly estimates:

Low dose (4mg/week): $150–$250
Mid (8mg/week): $250–$400
High (12mg/week): $400–$500

Grey market volatility means prices fluctuate; bulk buys save 20–30%.

Compounded Retatrutide Price via Telehealth Platforms

Telehealth platforms partner with compounding pharmacies for "personalized" retatrutide, escalating from 2mg to 12mg weekly. Monthly retatrutide price lands at $200–$600, including virtual consults and shipping.

These mimic trial protocols but lack FDA oversight. Dosing pens or multi-dose vials provided.

Monthly Compounded Costs: $200–$600 Based on Dose Escalation

Entry plans start ~$200 (induction), rising to $600 maintenance. Variability by provider; some bundle labs.

For detailed insights, see the retatrutide compounding pharmacy cost comparison, covering 2026 insurance prospects.

Dose-Specific Pricing: 2mg ($200–$300) to 12mg ($500–$600)

Adjusted for common ranges:

Month 1 (2mg/week): $200–$300
Month 2 (4mg): $250–$350
Month 3 (6mg): $300–$400
Month 4 (8mg): $400–$500
Month 5 (10mg): $450–$550
Month 6 (12mg): $500–$600

Wellness sites report these; higher ends reflect premium service.

Legal Gray Area for Compounding Before FDA Approval

Compounding falls under 503A/B rules for shortages, but retatrutide's investigational status invites scrutiny. FDA cautions on unapproved actives. Efficacy unproven outside trials.

Providers claim customization, but purity testing advised.

Free Access to Retatrutide: Clinical Trials and Compensation

Clinical trials offer risk-free, zero-cost retatrutide under medical supervision. Eli Lilly covers all expenses; perks include compensation.

Recruiting nationwide; BMI ≥27 often qualifies.[4]

Phase 3 Trials Status: TRIUMPH and TRANSCEND-T2D Programs

TRIUMPH-Outcomes (NCT06383390) evaluates CV/kidney benefits (~5 years, 27 visits).[2] TRANSCEND-T2D-1 completed topline March 2026 with strong A1c/weight data.[3] Dive into Retatrutide Phase 3 TRIUMPH trials completion dates for NDA impacts.

2,050 in TRANSCEND; obesity trials ongoing (NCT067856, NCT040567).

How to Join: Recruiting Sites on ClinicalTrials.gov

Search ClinicalTrials.gov?term=retatrutide for sites.[4] Criteria: adults 18+, specific conditions. Pre-screening telehealth available.

Urban centers like Yale (lead investigator Ania Jastreboff) active.[2]

Trial Perks: $0 Cost + Potential Compensation (Thousands of Dollars)

Drug, visits, labs free. Stipends: $500–$5,000+ for time/travel. Best retatrutide price: free with data contribution.

Commitment: 40 weeks to 5 years.

Projected Retatrutide Price After FDA Approval (2027–2028)

Commercial launch post-approval eyes $1,000–$1,500/month pre-insurance, akin to peers. Auto-injectors expected.

See retatrutide NDA submission timeline for regulatory path.

Estimated Commercial Cost: $1,000–$1,500/Month Pre-Insurance

High-dose kits ~$1,500; savings cards cap at $550 for eligible. Manufacturing scales post-approval.

Obesity market precedents guide Lilly's strategy.

Comparisons to Tirzepatide and Semaglutide Pricing

Drug	Monthly List Price	Weight Loss (High Dose)
Semaglutide (Wegovy)	$1,300–$1,350	15% (68 weeks)
Tirzepatide (Mounjaro/Zepbound)	$1,000–$1,300	22.5% (72 weeks)
Retatrutide (proj.)	$1,000–$1,500	24–29% (48–68 weeks)[1]

Retatrutide's edge may command premium.

Factors Influencing Launch Price and Insurance Coverage

Trial success, generics threat, production costs. Medicare Part D expanding for obesity post-2024 changes; commercial plans follow.

Launch Q1 2028 possible.

Retatrutide Legal Status and Availability Warnings

Retatrutide remains investigational; no FDA nod for human use.[2] Research-only sales dominate.

Human administration outside trials violates law.

FDA Status: Investigational, Not Approved for Human Use

Phase 3 only; prescribable solely in protocols.[2] ClinicalTrials.gov lists status.[4]

Research-Only Labels: 'Not for Human Consumption'

Mandatory disclaimers on vials. Violations risk fines/health issues. Explore compounding pharmacy access legal gray area for enforcement details.

Risks of Online Purchases and Illegitimate Sources

Contaminants, underdosing rampant. No FDA recourse; lab testing essential ($100+).

Trials safest.

Retatrutide Efficacy: Is the Price Worth It?

Phase 2/3: 24% loss (48 weeks, 12mg); 29% in osteoarthritis (68 weeks).[1] Women averaged 28.5%, men 21.2%.[1]

HbA1c -2.0%; 82% normalized.[1]

Weight Loss Results: 24–29% in Phase 2/3 Trials

100% ≥5% loss; dose-dependent[1]
~60–71 lbs average[1]
Superior pooled MD: -14.33% vs. placebo[1]

NEJM data.[1]

HbA1c Reductions and Cardiometabolic Benefits

-1.3–2.0% drop; 31% <5.7%.[1] Lipids, BP improved; no plateau.

Comparisons to Ozempic and Mounjaro

Retatrutide outperforms in shorter trials. Triple vs. single/dual justifies potential retatrutide price premium.

Retatrutide Safety Profile and Side Effects

Tolerability mirrors GLP-1s; 73–94% AEs (mostly mild), 4% serious (placebo-matched).[1] Dose titration key.

Common GI Issues: Nausea, Diarrhea (Dose-Dependent)

Effect	9mg	12mg	Placebo
Nausea	38%	43%	11%[1]
Diarrhea	35%	33%	13%[1]

Fades post-titration; 14–60% range.[1]

Serious Risks: Pancreatitis, Gallbladder, Heart Rate Changes

Pancreatitis: 0.4%[1]
Gallbladder: 1.1%[1]
HR +5–10 bpm[1]
Dysesthesia: 7% (Phase 3 signal)[1]

Thyroid class warning. Strategies in managing retatrutide dysesthesia at 12mg dose.

Management Strategies During Dose Escalation

Slow ramp halves GI; small meals, hydration. 7–9% discontinuation.

Monitor labs.

Alternatives to Retatrutide: Pricing Comparison

Approved GLP-1s offer immediate access at similar efficacy/price. Compounded cheaper pre-approval.

Alternative	Mechanism	Monthly Cost	Max Weight Loss
Semaglutide (Wegovy)	GLP-1	$1,300 (branded); $200–$400 compounded	15–20%
Tirzepatide (Zepbound)	GLP-1/GIP	$1,000–$1,300; $250–$500 compounded	20–22.5%
Retatrutide (proj.)	Triple	$1,000–$1,500	24–29%[1]

Pros of alternatives: Insured, proven. Cons: Less loss.

See compounded retatrutide cost before FDA approval.

Sourcing research‑grade retatrutide?

Ready to explore medical weight management?